Press releases

9 Jan 2023

UCB's financial update

6 Jan 2023

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

23 Dec 2022

UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

19 Dec 2022

FINTEPLA[®]▼ (fenfluramine) oral solution recommended for approval in the EU for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)

13 Dec 2022

UCB and Praxis Precision Medicines Announce Epilepsy Research Collaboration

12 Dec 2022

Changes in UCB’s Board of Directors

Press releases

Press releases

Search Press releases

UCB's financial update

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

FINTEPLA[®]▼ (fenfluramine) oral solution recommended for approval in the EU for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)

UCB and Praxis Precision Medicines Announce Epilepsy Research Collaboration

Changes in UCB’s Board of Directors

Choose a Country

UCB and Ailux Biologics Join Forces to Transform Biologics Research

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

Hidradenitis Suppurativa – Learn more about Hidradenitis Suppurativa an inflammatory skin disease

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2024 - Click here to access the report

UCBCares® - Discover what UCBCares® is about and the services they offer

Driving innovation forward: UCB unveils new R&D facility

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

BIMZELX[®]▼(bimekizumab) two-year data at EHSF 2025 demonstrate sustained disease control in...

RYSTIGGO[®]▼(rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two...

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

UCB completes sale of established brands and updates 2024 financial guidance

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

UCB's financial update

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

FINTEPLA[®]▼ (fenfluramine) oral solution recommended for approval in the EU for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)

UCB and Praxis Precision Medicines Announce Epilepsy Research Collaboration

Changes in UCB’s Board of Directors

Choose a Country